Inhibitors of peptidylarginine deiminases
Granted: March 4, 2025
Patent Number:
12240862
The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.
Blister pack
Granted: March 4, 2025
Patent Number:
D1064842
Blister pack
Granted: February 25, 2025
Patent Number:
D1063638
Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
Granted: February 18, 2025
Patent Number:
12227520
Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2, L, W1, W2, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Phospholipid compounds and uses thereof
Granted: January 28, 2025
Patent Number:
12208110
The present disclosure relates to compounds of Formula I, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for treatment of viral infections, for example for treatment of paramyxoviridae, pneumoviridae, picornaviridae, flaviviridae, filoviridae, arenaviridae, orthomyxovirus, and coronaviridae infections.
Crystalline forms of tenofovir alafenamide
Granted: January 21, 2025
Patent Number:
12202849
The present invention relates to novel crystalline forms of salts and/or co-crystals of tenofovir alafenamide, the pharmaceutical formulations, and the therapeutic uses thereof in treating viral infections.
MCL1 inhibitors
Granted: January 21, 2025
Patent Number:
12202842
The present disclosure generally relates to compounds of Formula (1) and pharmaceutical compositions that may be used in methods of treating cancer.
Processes and intermediates for preparing MCL1 inhibitors
Granted: January 21, 2025
Patent Number:
12202782
The present disclosure relates to methods and intermediates for the synthesis of certain compounds that inhibit MCL1, for use in the treatment of cancers.
Multi-specific antigen binding molecules targeting HIV and methods of use
Granted: January 14, 2025
Patent Number:
12195524
Provided are multi-specific antigen binding molecules, including bispecific antibodies, that bind to CD3 and an HIV antigen, including HIV envelope protein gp120. Also provided are methods of using such antigen binding molecules to treat or prevent HIV infection.
Therapeutics compounds for HIV virus infection
Granted: January 7, 2025
Patent Number:
12187753
The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.
Substituted pyridotriazine compounds and uses thereof
Granted: January 7, 2025
Patent Number:
12187734
The present disclosure relates generally to certain tricyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.
Compounds and methods for treatment of viral infections
Granted: December 31, 2024
Patent Number:
12180217
Compounds and methods of using said compounds, singly or in combination with additional agents, and salts or pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
GLP-1R modulating compounds
Granted: December 31, 2024
Patent Number:
12180197
The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
Salts and polymorphs of certain MCL-1 inhibitors
Granted: December 10, 2024
Patent Number:
12162896
The present disclosure relates salts and the crystalline forms of certain 3?,4,4?,5-tetrahydro-2H,2?H-spiro[benzo[b][1,4]oxazepine-3,1?-naphthalene] derivatives as well as pharmaceutical formulations and therapeutic uses thereof. The present disclosure also relates to preparing such salts, crystalline forms and pharmaceutical formulations.
MCL-1 inhibitors
Granted: December 10, 2024
Patent Number:
12162844
The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
Substituted pyrrolizine compounds and uses thereof
Granted: December 10, 2024
Patent Number:
12161625
This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
LPA receptor antagonists and uses thereof
Granted: November 12, 2024
Patent Number:
12139474
The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).
GLP-1R modulating compounds
Granted: October 22, 2024
Patent Number:
12121511
The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition.
Methods and intermediates for preparing therapeutic compounds
Granted: October 22, 2024
Patent Number:
12122765
The present disclosure relates to methods and intermediates useful for preparing a compound of formula I: or a co-crystal, solvate, salt or combination thereof.
Nucleoside phosphoramidate prodrugs
Granted: October 22, 2024
Patent Number:
12121529
Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
